CNS Refractory Tumors


Since initial studies started in 2009, Plex’s drug discovery program to discover dual-active inhibitors of Hsp90 and its mitochondrial homologue TNF Receptor Associated Protein-1 (TRAP1) has yielded multiple lead series with potent anti-cancer properties.

Preliminary studies have shown that one of our lead series has blood brain barrier penetrating properties. Our goal is to develop these dual HSP90/TRAP1 inhibitors as a treatment for CNS tumors that include glioblastoma multiforme, metastatic brain tumors, and CNS tumors associated with neurofibromatosis type 2.